Coronavirus / COVID

Latest News

Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 Vs Placebo
Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 Vs Placebo

June 29th 2025

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.

ACIP June 2025: COVID-19 Trends, Vaccine Updates, and Targeted Recommendations
ACIP June 2025: COVID-19 Trends, Vaccine Updates, and Targeted Recommendations

June 25th 2025

The Lingering Threat: Managing Severe COVID-19 in the Postpandemic Era
The Lingering Threat: Managing Severe COVID-19 in the Postpandemic Era

June 12th 2025

Novavax Reports Immune Responses and Safety in Phase 3 Trial of COVID-19-Influenza Combination Vaccine
Novavax Reports Immune Responses and Safety in Phase 3 Trial of COVID-19-Influenza Combination Vaccine

June 12th 2025

FDA Approves Moderna’s COVID-19 Vaccine
FDA Approves Moderna’s COVID-19 Vaccine

May 31st 2025

More News

© 2025 MJH Life Sciences

All rights reserved.